Roivant Sciences’ Priovant Therapeutics reported that brepocitinib, a dual JAK1/TYK2 inhibitor licensed from Pfizer, met proof‑of‑concept goals in cutaneous sarcoidosis — a rare inflammatory skin disease with no FDA‑approved treatments. The positive readout positions brepocitinib for pivotal testing and strengthens its potential as a differentiated inflammatory disease asset. The result could reshape Roivant’s rare disease strategy and support broader clinical development for indications where JAK/TYK2 modulation shows efficacy. The win also underscores ongoing private‑to‑public licensing pathways that move late‑stage assets into new corporate development engines.